You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

~ Buy the WELIREG (belzutifan) Drug Profile, 2024 PDF Report in the Report Store ~

WELIREG Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Welireg, and what generic alternatives are available?

Welireg is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-three patent family members in twenty-eight countries.

The generic ingredient in WELIREG is belzutifan. One supplier is listed for this compound. Additional details are available on the belzutifan profile page.

DrugPatentWatch® Generic Entry Outlook for Welireg

Welireg will be eligible for patent challenges on August 13, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 5, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for WELIREG?
  • What are the global sales for WELIREG?
  • What is Average Wholesale Price for WELIREG?
Summary for WELIREG
International Patents:53
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 29
Clinical Trials: 3
Patent Applications: 35
Drug Prices: Drug price information for WELIREG
What excipients (inactive ingredients) are in WELIREG?WELIREG excipients list
DailyMed Link:WELIREG at DailyMed
Drug patent expirations by year for WELIREG
Drug Prices for WELIREG

See drug prices for WELIREG

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for WELIREG
Generic Entry Date for WELIREG*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for WELIREG

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme Corp.Phase 1
Peloton Therapeutics, Inc.Phase 2

See all WELIREG clinical trials

US Patents and Regulatory Information for WELIREG

WELIREG is protected by four US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of WELIREG is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting WELIREG

Aryl ethers and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA, CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS, NOT REQUIRING IMMEDIATE SURGERY

Aryl ethers and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMED DEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA, CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS, NOT REQUIRING IMMEDIATE SURGERY


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMED DEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR

FDA Regulatory Exclusivity protecting WELIREG

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMEDDEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND 1 INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU (VHL) DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA (RCC), CENTRAL NERVOUS SYSTEM (CNS) HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS (PNET), NOT REQUIRING IMMEDIATE SURGERY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme WELIREG belzutifan TABLET;ORAL 215383-001 Aug 13, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Merck Sharp Dohme WELIREG belzutifan TABLET;ORAL 215383-001 Aug 13, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Merck Sharp Dohme WELIREG belzutifan TABLET;ORAL 215383-001 Aug 13, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Merck Sharp Dohme WELIREG belzutifan TABLET;ORAL 215383-001 Aug 13, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Merck Sharp Dohme WELIREG belzutifan TABLET;ORAL 215383-001 Aug 13, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for WELIREG

When does loss-of-exclusivity occur for WELIREG?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 7600
Patent: ÉTERES DE ARILO Y SUS USOS
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 14318025
Patent: Aryl ethers and uses thereof
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 19397
Patent: ARYLETHERS ET UTILISATIONS DE CEUX-CI (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

China

Patent: 5530923
Patent: Aryl ethers and uses thereof
Estimated Expiration: ⤷  Sign Up

Patent: 0372550
Patent: 芳基醚及其用途 (Aryl ethers and uses thereof)
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0191298
Estimated Expiration: ⤷  Sign Up

Patent: 0201701
Estimated Expiration: ⤷  Sign Up

Cuba

Patent: 385
Patent: COMPUESTOS ÉTERES DE ARILO ÚTILES PARA TRATAR CANCER DE CÉLULA RENAL
Estimated Expiration: ⤷  Sign Up

Patent: 160030
Patent: COMPUESTOS ÉTERES DE ARILO YÚTILES PARA TRATAR CANCER DE CÉLULA RENAL
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 23433
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 43784
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 2124
Patent: АРИЛЭФИРЫ И ИХ ПРИМЕНЕНИЯ (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 1690549
Patent: АРИЛЭФИРЫ И ИХ ПРИМЕНЕНИЯ
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 43784
Patent: ARYLÉTHERS ET UTILISATIONS DE CEUX-CI (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 17851
Patent: ÉTHERS D'ARYLE ET LEURS UTILISATIONS (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 17852
Patent: ÉTHERS D'ARYLE ET LEURS UTILISATIONS (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 86835
Patent: ÉTHERS D'ARYLE ET LEURS UTILISATIONS (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 21667
Patent: 芳基醚及其用途 (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 45462
Estimated Expiration: ⤷  Sign Up

Patent: 52080
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 3888
Patent: אתרים אריליים ושימושים שלהם (Aryl ethers and uses thereof)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 86940
Estimated Expiration: ⤷  Sign Up

Patent: 46733
Estimated Expiration: ⤷  Sign Up

Patent: 18039
Estimated Expiration: ⤷  Sign Up

Patent: 16534134
Patent: アリールエーテルおよびその使用
Estimated Expiration: ⤷  Sign Up

Patent: 19070043
Patent: アリールエーテルおよびその使用 (ARYL ETHER AND USE THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 19089855
Patent: アリールエーテルおよびその使用 (ARYL ETHER AND USE THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 19089856
Patent: アリールエーテルおよびその使用 (ARYL ETHER AND USE THEREOF)
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 43784
Estimated Expiration: ⤷  Sign Up

Patent: 17851
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 16002974
Patent: ETERES DE ARILO Y SUS USOS. (ARYL ETHERS AND USES THEREOF.)
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 6281
Patent: Aryl ethers and uses thereof
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 160434
Patent: ETERES DE ARILO Y SUS USOS
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 43784
Estimated Expiration: ⤷  Sign Up

Patent: 17851
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 43784
Estimated Expiration: ⤷  Sign Up

Patent: 17851
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 960
Patent: ARIL ETRI I NJIHOVA PRIMENA (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 953
Patent: ARIL ETRI I NJIHOVE UPOTREBE (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201601616S
Patent: ARYL ETHERS AND USES THEREOF
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 43784
Estimated Expiration: ⤷  Sign Up

Patent: 17851
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2153772
Estimated Expiration: ⤷  Sign Up

Patent: 160055199
Patent: 아릴 에테르 및 이의 용도 (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 39433
Estimated Expiration: ⤷  Sign Up

Patent: 84454
Estimated Expiration: ⤷  Sign Up

Patent: 23477
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 57071
Estimated Expiration: ⤷  Sign Up

Patent: 1605775
Patent: Aryl ethers and uses thereof
Estimated Expiration: ⤷  Sign Up

Patent: 1936572
Patent: Aryl ethers and uses thereof
Estimated Expiration: ⤷  Sign Up

Uruguay

Patent: 731
Patent: ÉTERES DE ARILO Y SUS USOS
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering WELIREG around the world.

Country Patent Number Title Estimated Expiration
Cyprus 1123433 ⤷  Sign Up
Israel 243888 אתרים אריליים ושימושים שלהם (Aryl ethers and uses thereof) ⤷  Sign Up
Portugal 3043784 ⤷  Sign Up
Denmark 3043784 ⤷  Sign Up
Hungary E052080 ⤷  Sign Up
European Patent Office 3417851 ÉTHERS D'ARYLE ET LEURS UTILISATIONS (ARYL ETHERS AND USES THEREOF) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.